Amendments to the Claims

1. (Currently amended) A pharmaceutical formulation comprising:

   a. 0.5 – 50 wt% of a compound of formula I;



I

wherein R^1 is hydrogen or alkyl having one to five carbon atoms; R^2 is hydrogen or C_1-C_4 alkyl or the group

$(H_2C)_n-N(A)(B)$ in which A and B independently denote hydrogen or C_1-C_4 alkyl and n is 1-4; R^3 and R^4 together with the atoms they are connected to form a heterocyclic, mono-, di-, or tricyclic ring system which is optionally substituted with C_1-C_4 alkoxy; R^5 is methyl or phenyl; and pharmaceutically acceptable salts thereof;

   b. 5 – 90 wt% of an alkali or alkaline earth metal carbonate;

   c. 5 – 90 wt% of an insoluble alkaline-earth metal salt of hydrogen phosphate; and ~~with the provisio that the formulation does not contain a substantial amount of a saccharide compound~~

   d. less than 5 wt% of a saccharide compound.

2. (Original) The formulation of claim 1, wherein the alkali or alkaline-earth metal carbonate is selected from magnesium carbonate, sodium hydrogen carbonate and sodium carbonate.

3. (Original) The formulation of claim 1, wherein the amount of the alkaline earth metal carbonate is at least the equivalent of the amount of the active compound of formula I.

4. (Original) The formulation of claim 1, wherein the compound of formula I is selected from the group containing enalapril, delapril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and pharmaceutically acceptable salts thereof.

5. (Original) The formulation of claim 1 wherein the formulation comprises in the range of about 1 – 15 wt% of the compound of formula 1.

6. (Original) The formulation of claim 1 wherein the formulation comprises in the range of about 25 – 75 wt% of the alkali or alkaline earth metal carbonate.

7. (Original) The formulation of claim 6 wherein the formulation comprises in the range of about 30 – 50 wt% of the alkali or alkaline earth metal carbonate.

8. (Original) The formulation of claim 1 wherein the formulation comprises in the range of about 15 – 75 wt% of the salt of an insoluble alkaline earth metal hydrogen phosphate.

9. (Original) The formulation of claim 1 wherein the formulation comprises in the range of about 25 – 50 wt% of the salt of an insoluble alkaline earth metal hydrogen phosphate.

10. (Previously presented) The formulation of claim 4 wherein the compound of formula I is quinapril or a pharmaceutically acceptable salt thereof.

11. (Previously presented) The formulation of claim 1 further comprising 0.5 – 50 wt% of a pharmaceutically active compound selected from the group consisting of diuretics, antitussives, antihistamines, decongestants and alkaloids.

12. (Previously presented) The formulation of claim 11, wherein the pharmaceutically active compound is selected from the group consisting of hydrochlorothiazide, dextromethorphan, dextromethorphan hydrobromide, noscapine, carbetapentane citrate, chlophedianol hydrochloride, chloepheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, phenyltoloxamine citrate, phenylephedrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, ephedrine, codeine phosphate, codeine sulfate and morphine.

13-14. (Cancelled)

15. (Previously presented) The formulation of claim 1, which contains less than 2 wt% of a saccharide compound.

16. (Previously presented) The formulation of claim 1, which does not contain a saccharide compound.